At the New York - Cornell Center for Lymphoma and Myeloma where I am clinical director, we have developed an outstanding team of physicians (including medical oncologists, radiation oncologists, pathologists, and others), nurses, and related health care personnel in order to optimally serve patients with these disorders. As we have a clinical focus in these areas, we are well versed in standard therapies, as well as their usual complications. Our experience with lymphoma and other treatment regimens is important to many patients undergoing therapy.

However, we are not satisfied with current outcomes for patients with lymphoma and myeloma as a group. We are working diligently to try to improve cure rates, as well as to improve remissions and extend life for other patients, while maintaining and improving its quality. Many of our patients are interested in clinical trials for their disorder, often in addition to "standard" therapies. Our focus has been primarily on "immunotherapies", which can work with the immune system to kill tumor cells.

These treatments take many forms, including monoclonal antibodies, radioactive monoclonal antibodies, and vaccine treatments. We also are studying various other new agents of this type in clinical trials. Many of these clinical trials are offered in conjunction with the National Cancer Institute, and our research program is otherwise in part also supported by the National Institutes of Health. Some clinical trials can be administered in conjunction with community oncologists, in order to minimize inconvenience and travel for the patient. Additional details are located in the "Research Profile" section on this page of the website.

Lymphomas as a group are a complex set of disorders. While many patients are treated here as their primary oncologist, others come for a second opinion while having their primary oncologic care with a local physician, having us follow along as needed. Others are referred (or otherwise seek care) for access to novel agents as part of clinical trials. We are pleased to provide care in any fashion which would be of assistance to patients, in order to help them achieve the best possible therapeutic results. Patients or physicians with any questions about our lymphoma and myeloma care programs, clinical trials, or related issues should feel free to contact us for more information.